RemeGen Stock price
AI Insights on RemeGen
Insights
Is RemeGen a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,100 stocks worldwide.
Key metrics
RemeGen Stock Analysis
Analyst Opinions
11 Analysts have issued a RemeGen forecast:
Analyst Opinions
11 Analysts have issued a RemeGen forecast:
RemeGen Events
Past Events
|
OCT
29
Q3 2026 Earnings Call
6 days ago
|
Don't miss a Thing! We will send you all news about RemeGen directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
RemeGen Co Ltd is a CN-based company operating in Biotechnology industry. The company is headquartered in Yantai, Shandong and currently employs 2,999 full-time employees. The company went IPO on 2020-11-09. RemeGen Co Ltd is a China-based company principally engaged in biopharmaceutical research, biopharmaceutical service, biopharmaceutical production and sale. The firm focuses on therapeutic antibody drugs such as antibody-drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies and bispecific antibodies. The Company’s main products include telitacicept, disitamab vedotin, RC28-E and others. The firm's products are mainly used to treat major diseases such as autoimmune diseases, oncology and ophthalmology. The firm mainly operates its businesses in the domestic and overseas markets.
| Head office | China |
| CEO | Mr. Fang |
| Employees | 3,048 |
| Website | www.remegen.cn |


